Consensus statement on the surgical management of vitiligo
Journal of Cutaneous and Aesthetic Surgery · 2025
DOI: 10.25259/jcas_117_2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous and Aesthetic Surgery, 2025. Verfasst von Yogesh M Bhingradia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Shivani Skin Care and Cosmetic Clinic, Surat, Gujarat, India. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Vitiligo is a chronic skin disorder characterized by the loss of melanocytes, leading to depigmented patches on the skin. The global lifetime prevalence of vitiligo diagnosed by a physician or dermatologist was estimated at 0•36% in the general population, 0•67% in the adult population adults, and 0•24% in the child population. Vitiligo prevalence was higher in adults than in children across all regions. Central Europe and south Asia reported the highest prevalence 0•52% and 0•52%, respectively, in the general population. Vitiligo significantly impacts patients’ quality of life, causing psychological distress and social stigmatization. While medical treatments such as corticosteroids and phototherapy exist, they often fail to achieve satisfactory repigmentation, particularly in extensive or recalcitrant cases. In recent years, surgical interventions have gained prominence as effective alternatives for managing vitiligo. Techniques such as autologous melanocyte transplantation, suction blister grafting, split-thickness skin grafting, and punch grafting offer promising repigmentation results. However, the lack of standardized protocols and guidelines for vitiligo surgery presents challenges in patient selection, procedural approaches, and post-operative care. This study aims to review current surgical techniques, assess patient-specific factors influencing surgical success, and evaluate long-term outcomes, including repigmentation rates and patient satisfaction. Key factors include disease stability, lesion characteristics, and the involvement of exposed areas. Moreover, the study emphasizes the importance of post-operative adjuvant therapy, such as topical tacrolimus and excimer therapy, to enhance surgical outcomes. By establishing evidence-based protocols for vitiligo surgery, this study seeks to improve treatment efficacy and patient care, addressing gaps in current practices and advancing the field toward more consistent and successful outcomes in vitiligo management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shivani Skin Care and Cosmetic Clinic, Surat, Gujarat, India.
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Dermatology, South Mumbai Dermatology Clinic, Jaslok Hospital, Mumbai, India.
- Department of Dermatology, Vedanta Institute of Medical Sciences, Palghar, Maharashtra, India.
- Department of Dermatology, Kiran Hospital, Surat, Gujarat, India.
- Cutis Institute, Kozhikode, Kerala, India.
Zitieren
APA
Bhingradia, Y. M., Gupta, S., Ghia, D., Shah, S., Patel, N. K., Salim, T., Kumari, P., Vasudevan, B., Shah, S., Jain, N., Borkhatariya, P. B., Mitra, D., & Prasad, D. (2025). Consensus statement on the surgical management of vitiligo. Journal of Cutaneous and Aesthetic Surgery. https://doi.org/10.25259/jcas_117_2024
Vancouver
Bhingradia YM, Gupta S, Ghia D, Shah S, Patel NK, Salim T, et al. Consensus statement on the surgical management of vitiligo. Journal of Cutaneous and Aesthetic Surgery. 2025. doi:10.25259/jcas_117_2024
BibTeX
@article{Bhingradia2025,
author = {Bhingradia, Yogesh M and Gupta, Somesh and Ghia, Deepti and Shah, Samkit and Patel, Nandita Krishnagopal and Salim, T and Kumari, Pradeep and Vasudevan, Biju and Shah, Swapnil and Jain, Nitin and Borkhatariya, Piyush B and Mitra, Debdeep and Prasad, Davinder},
title = {Consensus statement on the surgical management of vitiligo},
journal = {Journal of Cutaneous and Aesthetic Surgery},
year = {2025},
doi = {10.25259/jcas_117_2024}
}
EUVIMED